$ESPR: Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical company focused on developing and commercializing treatments for cardiovascular diseases. The company's lead product is Nexletol (bempedoic acid), a cholesterol-lowering medication that is currently approved in the United States and Europe. Esperion is also developing a second cholesterol-lowering medication, ezetimibe/bempedoic acid, which is currently in Phase 3 clinical trials.

Esperion was founded in 2008 and is headquartered in South San Francisco, California. The company's stock is traded on the Nasdaq stock exchange under the ticker symbol "ESPR."

Esperion's business model is to develop and commercialize innovative therapies for cardiovascular diseases. The company's focus is on cholesterol-lowering medications, which are a large and growing market. Esperion believes that its products have the potential to make a significant difference in the lives of patients with cardiovascular disease.

Esperion's lead product, Nexletol, is a once-daily oral medication that works by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol. Nexletol is approved in the United States and Europe for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH), a genetic condition that causes high cholesterol levels. Nexletol is also being studied for the treatment of other lipid disorders, such as primary hypercholesterolemia and mixed dyslipidemia.

Esperion's second product candidate, ezetimibe/bempedoic acid, is a combination of two cholesterol-lowering medications. Ezetimibe is a well-established drug that works by blocking the absorption of cholesterol from the gut. Bempedoic acid is a newer drug that works by inhibiting the enzyme HMG-CoA reductase. Ezetimibe/bempedoic acid is currently in Phase 3 clinical trials for the treatment of adults with HeFH and primary hypercholesterolemia.

Esperion is a clinical-stage biopharmaceutical company with a promising pipeline of cholesterol-lowering medications. The company's lead product, Nexletol, is already approved in the United States and Europe, and its second product candidate, ezetimibe/bempedoic acid, is in Phase 3 clinical trials. Esperion is well-positioned to capitalize on the large and growing market for cholesterol-lowering medications.

The company's stock price has been volatile in recent years, but it has been on an upward trend in the past few months. Esperion is currently trading at around $30 per share, and analysts have a price target of $115 per share, which represents an upside potential of over 300%.

Overall, Esperion is a risky but potentially rewarding investment. The company has a promising pipeline of cholesterol-lowering medications, but it is still in the early stages of development. Investors should carefully consider the risks and rewards before investing in Esperion.

Here are some of the risks associated with investing in Esperion:

• The company is still in the early stages of development, and there is no guarantee that its products will be successful.
• The company is facing competition from other pharmaceutical companies that are developing cholesterol-lowering medications.
• The company's stock price is volatile, and it could experience significant swings in the future.

Here are some of the potential rewards of investing in Esperion:

• The company has a promising pipeline of cholesterol-lowering medications that could be blockbuster products.
• The company is well-positioned to capitalize on the large and growing market for cholesterol-lowering medications.
• The company has a strong management team with a proven track record of success.

Overall, Esperion is a risky but potentially rewarding investment. Investors should carefully consider the risks and rewards before investing in Esperion.